Physician profile
Eric Edward Coronato
NPI 1740304419
$7,298.59
in general payments reported to CMS, 2019-2025
40 companies · $903 in 2025
The $903 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $579 · 2021: $712 · 2022: $620 · 2023: $1,021 · 2024: $2,531 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,398 · Travel and Lodging: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,398.45 |
| Travel and Lodging | $1,056.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,613.16 | 2020-2024 | Axonics, Bulkamid |
| Procept Biorobotics Corporation | $750.21 | 2024-2025 | Aquabeam System |
| Boston Scientific Corporation | $597.96 | 2019-2025 | Axonics, Spaceoar Vue System - 10ml, Watchman Flx |
| Endo Pharmaceuticals INC. | $567.78 | 2019-2023 | Edex, Xiaflex, Aveed |
| Janssen Biotech, INC. | $397.09 | 2019-2024 | Erleada, Akeega |
| Medtronic USA, INC. | $292.93 | 2019-2020 | |
| Neotract INC. | $280.62 | 2019 | |
| Abbvie INC. | $222.04 | 2019-2025 | Botox |
| Astellas Pharma US INC | $215.35 | 2019-2023 | Myrbetriq |
| Antares Pharma, INC. | $211.08 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Sumitomo Pharma America, INC. | $169.02 | 2023-2025 | Gemtesa |
| Myriad Genetic Laboratories, INC. | $161.13 | 2021-2024 | Prolaris |
| Medtronic, INC. | $160.06 | 2021-2025 | Interstim |
| Bayer Healthcare Pharmaceuticals INC. | $156.46 | 2020-2024 | |
| Coloplast Corp | $143.58 | 2021-2025 | Self-Cath, Speedicath, Porges Coloplast |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $137.48 | 2024-2025 | Aveed, Xiaflex |
| Allergan, INC. | $127.36 | 2019-2021 | |
| Olympus America INC. | $85.53 | 2023-2025 | Itind System |
| C. R. Bard, INC. & Subsidiaries | $83.43 | 2019-2025 | Magic3 Go Intermittent Urinary Catheter, Bard Urinary Drainage Bag |
| Halozyme INC | $82.37 | 2023 | |
| Ferring Pharmaceuticals INC. | $71.59 | 2019-2025 | Adstiladrin |
| Myovant Sciences INC. | $71.00 | 2021-2022 | |
| Tolmar, INC. | $70.32 | 2023 | |
| Olympus Corporation of The Americas | $65.00 | 2023 | Itind System |
| Pfizer INC. | $61.56 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $59.94 | 2019-2023 | Provenge |
| Merck Sharp & Dohme LLC | $55.26 | 2023-2025 | Keytruda, Lynparza |
| Valencia Technologies Corporation | $52.40 | 2023 | Ecoin Device Kit |
| Karl Storz Endoscopy-America | $49.80 | 2021 | |
| Blue Earth Diagnostics | $40.49 | 2019-2020 | |
| Urovant Sciences INC | $35.99 | 2021-2022 | |
| Teleflex LLC | $33.29 | 2024 | Urolift |
| Progenics Pharmaceuticals, INC. | $32.45 | 2025 | |
| Urogen Pharma, INC. | $28.24 | 2022-2024 | |
| Becton, Dickinson and Company | $28.19 | 2024-2025 | Bard Urinary Drainage Bag |
| 180 Medical, INC. | $23.14 | 2023 | Gentlecath |
| Novartis Pharmaceuticals Corporation | $18.62 | 2022 | |
| Convatec INC. | $17.53 | 2022 | |
| Laborie Medical Technologies Corp. | $17.17 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Coronato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.